Naltrexone Has Variable and Schedule-Dependent Effects on Oral Squamous Cell Carcinoma Cells.

ABSTRACT: Oral squamous cell carcinoma (OSCC) is marked by profound differences in survival between the localized and disseminated disease, estimated to result in a 70% and less than a 40% five-year survival rate with surgical and/or radiation approaches (in localized cases) and chemotherapy (in metastatic cases), respectively. Given the suboptimal efficacy of current management options, new therapeutic approaches are needed to supplement existing chemotherapies and improve outcomes. One emerging therapeutic option is naltrexone (NTX), an opioid antagonist that has shown promising outcomes at low doses in other forms of cancer. This study sought to determine the effectiveness of intermittent dosing of naltrexone on oral cancer cell survival, either as a single agent or in combination with traditiona

SUBMITTER: Kazmi S 

PROVIDER: S-EPMC12609663 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature